Crane Biosciences
Crane Biosciences develops gene and RNA therapies that use red blood cell–derived nanoparticles to deliver treatments while avoiding immune detection. The company engineers RBC-derived nanoparticles (RBCNPs) to encapsulate RNA payloads and reduce immune system reactions, and applies AI to design and optimize candidates. It operates as a biotech therapeutics developer combining nanotechnology, RNA therapeutics, and computational drug‑discovery tools. Based at Imperial College London with academic and accelerator partners, Crane advances programs for genetic and other hard-to-treat diseases toward clinical development.
Crane Biosciences
Crane Biosciences develops gene and RNA therapies that use red blood cell–derived nanoparticles to deliver treatments while avoiding immune detection. The company engineers RBC-derived nanoparticles (RBCNPs) to encapsulate RNA payloads and reduce immune system reactions, and applies AI to design and optimize candidates. It operates as a biotech therapeutics developer combining nanotechnology, RNA therapeutics, and computational drug‑discovery tools. Based at Imperial College London with academic and accelerator partners, Crane advances programs for genetic and other hard-to-treat diseases toward clinical development.